![](https://www.jhconline.com/wp-content/uploads/Sean-Salmon.png)
December 15, 2020 – Medtronic plc (Dublin, Ireland) announced that Sean Salmon, EVP and president, Diabetes Operating Unit, was named EVP and president, Cardiovascular Portfolio, effective January 1.
Salmon will also continue to lead the Diabetes Operating Unit and continue to serve on the company’s Executive Committee.
With his new additional Cardiovascular responsibilities, Salmon will oversee the Cardiovascular operating units, ensuring appropriate capital allocation to optimize Medtronic’s growth and profitability, overall business performance, and innovation designed to drive continued market expansion and increased share.
Salmon joined Medtronic in 2004 and spent 15 years in increasingly senior management roles within Cardiovascular, including leading the Coronary and Renal Denervation, Peripheral, Cardiac Surgery, and Structural Heart businesses, before being named the leader of Medtronic Diabetes and a member of the Medtronic Executive Committee in 2019.
He succeeds Mike Coyle, who will leave Medtronic effective December 31 to accept a CEO role of iRhythm Technologies, Inc. (San Francisco, CA), a digital healthcare solutions company focused on the advancement of cardiac care.